Thank you to all of our speakers, sponsors and colleagues for making this event a great success!
Highlights from the Symposium…free access
Did you miss the RE Symposium or do you need a refresher course?
Take a few moments to view this audio/video presentation which quickly highlights the key issues of the event.
Our speakers and attendees discussed the need for data, managing rising specialty drug costs, the trust issue between the healthcare players, and what constitutes value today – and, as importantly, what doesn’t.
Play Slideshow
To access all of the audio presentations click here
“The Evidence Challenge of Rational Reimbursement”
Presented by Roger Longman, CEO, Real Endpoints
One way for payers to get a handle on drug spending and simultaneously support real medical innovation is comparative efficacy – the transformational fuel for evidence-based prescribing and reimbursement. But self-interest, academic perfectionism, government and corporate priorities, political restrictions and accounting bureaucracy are all getting in the way of rational reimbursement decisions. The answer: knowing when to go with “good enough”.
Play complimentary recording here:
Download audio here: Audio
Download PDF slides here:Slides
Access all audio recordings and slides from the conference.
Simply fill out a short form and gain access to the
complete conference recordings. Access form here
One major topic of conversation during the Real Endpoints Symposium: what constitutes value in today’s healthcare environment — and, as importantly, what doesn’t. As efforts to define value –and amass evidence to demonstrate it –continue, the one metric that clearly sways payers is total cost-of-care.
Download PDF highlights on "Value"
Controlling run-away specialty drug costs, especially high-priced oncologics, is the next big challenge for payers and employers. Trouble is, comparative data measuring the effectiveness of one therapy relative to another can be hard to find – if it’s even available. Moreover, current solutions like clinical pathways and narrow networks won’t be enough to solve the specialty drug cost problem.
Download PDF highlights on "Specialty Drugs"
Symposium speakers discussed a variety of challenges, from controlling rising specialty drug costs to the creation of objective, transparent sources of comparative effectiveness. But the biggest challenge of all: establishing trust between the various healthcare players.
There are many steps pharmas could take to build trust…if all else fails, look to risk-sharing agreements.
Download PDF highlights on "Trust"
Objective, real world data is the new coin of the US healthcare realm. Using such outcomes and trend data, providers and payers will finally be able to make evidence-based medical decisions. The result? Smarter, more cost-effective healthcare.
If only it were that simple.
Download PDF highlights on "Data"
Thought leaders
- Lewis Sandy, MD
SVP, Clinical Advancement, UnitedHealth - Michael Sherman, MD
CMO, Harvard Pilgrim - Robert Galvin, MD
CEO, Equity Healthcare - Michael Kolodziej, MD
National Medical Director, Oncology Solutions, Office of the CMO, Aetna - Annalisa Jenkins, MD
EVP, Head of Global Development, Merck Serono
- Peter Bach, MD
Director of the Center for Health Policy & Outcomes, Memorial Sloan Kettering - Jack Bailey
SVP, Policy, Payers & Vaccines, GlaxoSmithKline - Steve Wooding
VP, Head of Market Access, Janssen EMEA, J&J - Jay Galeota
President, Hospital and Specialty Care, Merck & Co. Inc. - …And more!
meet the speakers
Who Attended:
Payers and Risk-Sharing Providers
- CEO, CFO
- Medical Director
- Pharmacy Director
- Health Economics
- Technology Assessment
Biopharma/Med Device/Diagnostics
- CEO, CFO
- Senior Clinical Development
- Managed Markets
- Senior Marketing Executives
- Brand Management
- HEOR